Phase 2CompletedAge-related condition

A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms (SWITCH-1)

A Double-Blind, Randomised, Placebo Controlled, Adaptive Design Study of the Efficacy, Safety and Pharmacokinetics of NT-814 in Female Subjects With Moderate to Severe Vasomotor Symptoms Associated With the Menopause

Sponsor
Bayer (Industry)
Enrollment
199 enrolled
Conditions
Menopause; Hot Flashes; Night Waking
Interventions
Elinzanetant (BAY3427080); Placebo
Ages
adults, older adults
Registry
NCT03596762, EUCTR2018-002763-26

Full record on ClinicalTrials.gov

From the registry

The purpose of this study is to determine the effectiveness of BAY3427080 (NT-814), taken once a day, in the treatment of troublesome post-menopausal symptoms.

Primary outcomes

  • Mean Change From Baseline in Mean Daily Frequency of Moderate and Severe Hot Flushes From Baseline to Week 4
  • Mean Change From Baseline in Mean Daily Frequency of Moderate and Severe Hot Flushes From Baseline to Week 12
  • Mean Change From Baseline in Mean Severity of Moderate and Severe Hot Flushes From Baseline to Week 4
  • Mean Change From Baseline in Mean Severity of Moderate and Severe Hot Flushes From Baseline to Week 12

History

  1. Results first posted

  2. Last registry update

  3. Primary completion

  4. Started

  5. Registered

In the news